| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w15574 |
| 来源ID | Working Paper 15574 |
| An Economic Evaluation of the War on Cancer | |
| Eric C. Sun; Anupam B. Jena; Darius N. Lakdawalla; Carolina M. Reyes; Tomas J. Philipson; Dana P. Goldman | |
| 发表日期 | 2009-12-10 |
| 出版年 | 2009 |
| 语种 | 英语 |
| 摘要 | For decades, the US public and private sectors have committed substantial resources towards cancer research, but the societal payoff has not been well-understood. We quantify the value of recent gains in cancer survival, and analyze the distribution of value among various stakeholders. Between 1988 and 2000, life expectancy for cancer patients increased by roughly four years, and the average willingness-to-pay for these survival gains was roughly $322,000. Improvements in cancer survival during this period created 23 million additional life-years and roughly $1.9 trillion of additional social value, implying that the average life-year was worth approximately $82,000 to its recipient. Health care providers and pharmaceutical companies appropriated 5-19% of this total, with the rest accruing to patients. The share of value flowing to patients has been rising over time. These calculations suggest that from the patient's point of view, the rate of return to R&D investments against cancer has been substantial. |
| 主题 | Health, Education, and Welfare ; Health ; Education ; Poverty and Wellbeing |
| URL | https://www.nber.org/papers/w15574 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/573250 |
| 推荐引用方式 GB/T 7714 | Eric C. Sun,Anupam B. Jena,Darius N. Lakdawalla,et al. An Economic Evaluation of the War on Cancer. 2009. |
| 条目包含的文件 | ||||||
| 文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
| w15574.pdf（319KB） | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
